By
Sequella
Published: Dec. 21, 2012, 10:27 p.m.·
Tags:
None
The trial will compare the effects of an optimized background drug regimen alone with an optimized background regimen plus SQ109 in MDR-TB patients.
Read More →
By
Sequella
Published: July 27, 2012, 4:05 a.m.·
Tags:
None
Maxwell Biotech Venture Fund’s portfolio company, Infectex, receives Russian regulator’s approval to conduct pivotal clinical trial for Sequella’s antibiotic, SQ109, for tuberculosis.
Read More →
